Open Access Highly Accessed Research article

A novel model-based approach for dose determination of glycopyrronium bromide in COPD

Helen Arievich1, Tim Overend2*, Didier Renard3, Michael Gibbs2, Vijay Alagappan2, Michael Looby3 and Donald Banerji4

Author Affiliations

1 Medars GmbH, Berlin, Germany

2 Novartis Horsham Research Centre, Wimblehurst Road, Horsham, West Sussex, RH12 5AB, UK

3 Novartis Pharma AG, Basel, Switzerland

4 Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

For all author emails, please log on.

BMC Pulmonary Medicine 2012, 12:74  doi:10.1186/1471-2466-12-74

Published: 8 December 2012

Additional files

Additional file 1:

Appendix 1. Study centers and ethics committee.

Format: DOC Size: 44KB Download file

This file can be viewed with: Microsoft Word Viewer

Open Data

Additional file 2:

Appendix 2. Analysis methodology.

Format: DOC Size: 83KB Download file

This file can be viewed with: Microsoft Word Viewer

Open Data